Generic zyban his initial diagnosis was viral gastroenteritis. The filing of patent-infringement generic zyban lawsuits is just one of the tactics these companies use in an attempt to extend marketing exclusivity of a product. Important factors that could cause or contribute to such differences include Teva’s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva’s ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U. IMPAX Laboratories is headquartered in Hayward, Calif. , and has a full range of capabilities in its Hayward and Philadelphia facilities. IMPAX’s ANDA filings with the Food and Drug Administration (FDA) contain Paragraph IV certifications under the Hatch-Waxman Amendments stating IMPAX’s belief that its bupropion hydrochloride extended release tablets do not generic zyban infringe the Glaxo Wellcome listed patents on Wellbutrin SR and Zyban. Twelve of these filings were made under Paragraph IV of the Hatch-Waxman Amendments. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of litigation and future product launches; government regulation generally; competition; manufacturing capacities and output; litigation asserting the Company’s infringement of third party proprietary rights; commercial obstacles to the successful introduction of brand products generally; exclusion of Andrx’s brand products from formularies; the success of Andrx’s joint ventures; product liability claims; rising costs and availability of insurance, including product liability insurance; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals; Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U. (NASDAQ:TEVA) pertaining to pending Abbreviated New Drug Applications (ANDAs) for bioequivalent versions of Wellbutrin(R) SR and Zyban(R) (Bupropion Hydrochloride) 100 mg and 150 mg Extended Release Tablets filed by Andrx, as well as by the Company. Under the Company’s previously announced Exclusivity Transfer Agreement with Impax and a subsidiary of Teva, Andrx is entitled to a share of the profits derived from Teva’s sale of this product for a 180-day period. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. Sales of generic zyban approximately $1. 6 billion for the twelve-month period ending March 31, 2003 according to IMS. CONTACT: David Myers, Jr. , Manager, Products & Communications, +1-973-993-4503, dmyers@actavis. Com, or Hjordis Arnadottir, generic zyban corporate Communications, +1-354-535-2300, harnadottir@actavis. Com, both of Actavis generic zyban group Web site: http://www. Us/A confused, agitated, and combative patient was admitted to an ED with severe nausea, vomiting, and generic zyban a reported seizure. The expedited review is part of a new FDA initiative to help speed low-cost HIV medicines to those in need in Generic zyban developing countries. Impax Corporation’s ("Impax") ANDA for this strength has now been approved, and Teva Pharmaceutical Industries Ltd. Such risks and uncertainties include, but are not limited to, Impax’s ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, Impax’s ability to successfully develop and commercialize pharmaceutical products, Impax’s reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in Impax’s filings with the Securities and Exchange Commission. Hydration and discontinued bupropion for 24 hours, his gastrointestinal and neurologic problems resolved and he was discharged. Forward-looking generic zyban statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise. Business Editors/Health/Medical Writers JERUSALEM–(BUSINESS WIRE)–July 31, 2003 Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that, pursuant to its July 2003 agreement with Andrx Corporation and Impax Laboratories, Inc. , it has begun commercially shipping Bupropion Hydrochloride 150 mg Controlled Release Tablets. Such statements are based on current expectations and involve a number of known and unknown risks and Generic zyban uncertainties that could cause Impax’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Said: "These approvals further enhance our strength in the area of modified release products and provide Generic zyban valuable options to our customers and patients. " About Actavis Actavis is one of the world’s leading generic pharmaceutical companies specializing in the generic zyban development, manufacture and sale of generic pharmaceuticals.
13 Mar 10
